At a Wall Street Journal event during the World Economic Forum in Davos, Pfizer CEO Albert Bourla labeled Robert F. Kennedy’s stance on vaccines “anti-science,” asserting that productive health policy dialogue breaks down when immunization enters the conversation. Bourla called for a change in leadership at the U.S. Department of Health and Human Services to overcome what he sees as an ideological barrier to meaningful vaccine progress. Beyond the debate over vaccines, he cautioned that cuts to federal research funding have weakened America’s global position: Harvard, MIT and Stanford once occupied the majority of top-tier health research slots, but today Chinese institutions hold roughly 80% of those positions. He highlighted reforms in China’s regulatory framework and intellectual property protections as catalysts for rapid expansion of domestic pharmaceutical innovation, urging U.S. policymakers to focus on bolstering competitiveness rather than attempting to contain China’s rise.

Pfizer is trading at one of its lowest valuations in over a decade, with a forward price-earnings ratio below 9 and a dividend yield near 6.7%, yet shares have remained flat over the past year. Skeptics point to looming patent expirations on flagship drugs such as Eliquis, Vyndaqel, Ibrance and Xtandi and revenue guidance of $59.5 billion to $62.5 billion for the current year—slightly below the prior year’s $62 billion—to argue the company may face declining sales and higher R&D spending. Supporters counter that Pfizer’s strategic acquisitions, including its 2023 purchase of oncology specialist Seagen and the recent acquisition of Metsera to enter the GLP-1 space, position the company for a new growth phase. They view the current valuation as an opportunity to buy into a leading healthcare franchise with substantial cash flow and a robust pipeline of next-generation therapies.